2023-04-20 15:53:00
A study conducted regarding the usefulness of the combined booster vaccine adapted to the Omicron strain found: a 72% reduction in the risk of hospitalizations and a 68% reduction in mortality from the corona virus among adults aged 65+. This is a comprehensive study that tested the usefulness of the Omicron adjusted vaccine dose in preventing hospitalizations and mortality
A study conducted in general regarding the usefulness of the combined booster vaccine adapted to the Omicron strain found: a 72% reduction in the risk of hospitalizations and a 68% reduction in mortality from the corona virus among adults aged 65+. This is a comprehensive study published in Lancet Infectious Diseases, which tested the usefulness of the Omicron adjusted vaccine dose in preventing hospitalizations and mortality. Close to the publication of the results, the FDA and the CDC approved a second booster dose adapted to omkiron for those aged 65+ and immunosuppressed
Using advanced statistical methods, the team of researchers analyzed the data of Klalit patients in order to examine the usefulness of the vaccine dose adapted to the omachiron strain in preventing hospitalizations and deaths from the corona disease among those aged 65 and over. The research was led by Klalit’s Community Medicine Department in collaboration with the Faculty of Health Sciences at Ben-Gurion University of the Negev and the Laboratory for Maximizing Health Outcomes at Sapir College.
At the end of 2022, it was recommended by the Ministry of Health in Israel, after approval by the FDA, to be vaccinated with a vaccine dose adapted to the Omicron strain, provided that at least three months have passed since receiving the last vaccine dose or recovery. The vaccine will be preferred for people at high risk of serious illness from the corona virus, including those aged 65 and over.
The study by Klalit, which was published this weekend in the prestigious scientific journal Lancet Infectious Diseases, followed all the members of Klalit aged 65 and older who are eligible for the vaccine, and compared the rates of hospitalizations and deaths from corona in the population who received the vaccine versus those who did not receive it. This article is an update of the initial results published by the General in a preliminary publication on January 8 of this year.
The follow-up was carried out after the approval of the Omicron-adapted vaccine in Israel, between the dates September 27, 2022 and January 25, 2023. The researchers reviewed data from 569,519 Clalit patients. The research method included multivariate adjustment for a variety of mortality risk factors, in order to neutralize possible biases that could arise from differences in age, sex, socioeconomic status or co-morbidity between the populations. This is the largest group size that allowed an accurate assessment of the relationship between receiving the vaccine dose and hospitalization and mortality rates resulting from corona illness.
The research findings:
The average age of the study population was 75. At the end of the study period, 24% of this population received the Omicron adapted vaccine. Among the recipients of the vaccine dose, a 72% reduction in hospitalization rates and a 68% reduction in death rates from corona was observed, compared to the group that was not vaccinated with the Omicron vaccine.
According to Dr. Doron Netzer, head of the medical department in the general community: “With the approval of the Omicron-adapted vaccine, the question arose regarding its usefulness in preventing serious morbidity and mortality. The vaccine was approved by the FDA in an emergency procedure without having conducted controlled effectiveness studies to prevent a serious disease, therefore there was uncertainty in the world about its usefulness and affected the degree of compliance to the vaccine. The results of the study we conducted show that the vaccine adapted to Leumicron is significantly associated with reducing the risk of hospitalization and mortality from corona. The publication of the findings of this research, the first in the world, regarding the vaccine adapted to the Omicron (bivalent) strain, is an important pillar for completing the administration of this vaccine in at-risk populations. “Close to the publication of the results of the study, the FDA and the CDC approved a second booster dose adapted to Omkiron for people aged 65+ and immunocompromised.”
The observational study was carried out on the basis of the computerized databases of Klalit, in accordance with the approval of the Institutional Helsinki Committee. The research was carried out without support from any external source.
#booster #vaccine #Omicron #strain #results #reduction #risk #hospitalization